Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

CompletedOBSERVATIONAL
Enrollment

790

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

December 4, 2022

Study Completion Date

December 4, 2022

Conditions
COVID-19
Interventions
OTHER

Previously admitted COVID-19 patients in intensive care units

Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission

Trial Locations (5)

4029

Royal Brisbane and Women's Hospital, Herston

27599

University of North Carolina, Chapel Hill

632004

Christian Medical College, Vellore

Unknown

Tan Tock Seng Hospital, Singapore

Siriraj Hospital, Bangkok

All Listed Sponsors
collaborator

Merck Sharp & Dhome (Australia) Pty. Ltd.

UNKNOWN

collaborator

Christian Medical College, Vellore, India

OTHER

collaborator

Tan Tock Seng Hospital

OTHER

collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

collaborator

Siriraj Hospital

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

lead

The University of Queensland

OTHER